Percutaneous Transhepatic Cholangiography Versus Endoscopic Ultrasound Guided Biliary Drainage (PETRUS)

Percutaneous Transhepatic Cholangiography Versus Endoscopic Ultrasound Guided Biliary Drainage in Advanced Biliary Tract Malignancy That Failed ERCP (PETRUS Study): A Randomized Pilot Study

Patients with obstructive jaundice due to locally advanced/metastatic malignancy with dilated intrahepatic bile ducts will be recruited from the department of Gastroenterology and Hepatology at the University Hospital of Leuven.

This population will have failed ERCP or will be considered when ERCP is not possible due to altered surgical anatomy.

Patients will be randomized to either PTC or EUS guided biliary drainage

Study Overview

• Status: Unknown
• Conditions: Malignant Biliary Obstruction
• Intervention / Treatment: Procedure: Percutaneous transhepatic cholangiography vs. endoscopic biliary drainage

Detailed Description

Background:

Advanced biliary tract malignancy complicated by obstructive jaundice has been traditionally managed by palliative stent placement at ERCP. In 3-12% of patients with advanced disease tumour involvement of the small bowel or peri-ampullary region may preclude the use of ERCP necessitating percutaneous transhepatic biliary drainage (PTBD) or surgery1. However these techniques have been associated with high complication rates and significant morbidity2. PTBD necessitates traversing the parietal and visceral peritoneum causing a potential for a bile leak and bleeding into the peritoneal cavity. This procedure is also associated with significant pain, lengthy hospital stays and an overall reduction in quality of life, and even procedure related mortality. Indeed the Society of Interventional Radiology (SIR) quality improvements guidelines established the procedural risk of severe major complications including sepsis, bleeding and procedural related death at 2.5% and less severe complications including pain and prolonged hospital admissions at 20%.

In recent years various groups have described endoscopic ultrasound guided access of the left system allowing placement of metal or plastic stents either across the distal stricture or deploying the stent in the stomach (hepatico-gastrostomy), with high technical success3. Retrograde cannulation normally performed from the duodenal bulb allows access to the biliary tract above a malignant stricture with the intent to either pass a guide wire through the papilla and then perform a rendezvous procedure, or the placement of a covered metal stent into the stomach (choledochoenterostomy)10. Cannulation of a dilated segment 2 or 3 sectoral duct is also possible from the proximal stomach where the endoscopist performs all procedures in an antegrade fashion5. Currently these procedures are selectively performed in centres by expert endoscopists from mainly tertiary care academic expert centres including in Leuven. Collectively EUS biliary drainage is technically successful in 75-92% of cases, however reports of bile leaking and peritonitis have been described5.

Various obstacles however still exist to extend the general applicability of this technique outside expert centres. Firstly, no randomized control trials exist comparing the safety and efficacy of EUS biliary access to Percutaneous Transhepatic Cholangiography (PTC). Secondly, current endoscopic techniques utilize standard endoscopic accessories not specifically developed to be utilized within the biliary system when advanced through the gastric wall. Thirdly, specific EUS strategies are needed to prevent or reduce complications associated with percutaneous approaches.

Concept and preliminary experimental data

Hypothesis

Based on the literature we hypothesize that:

• Endoscopic ultrasound guided biliary drainage is more effective than percutaneous biliary drainage in the management of obstructive jaundice
• EUS guided biliary drainage is associated with a reduced incidence of major (bile peritonitis, procedure related mortality, hematobilia) and minor (abdominal pain, prolonged hospital stay) complications.
• EUS guided biliary drainage is more cost effective compared to percutaneous biliary drainage

Aims of proposed research

Based on the current literature we propose a randomized pilot study assessing the following specific end points

• EUS biliary drainage is as effective as percutaneous biliary drainage in achieving resolution of cholestasis
• EUS biliary drainage is not associated with an increased risk of complications compared to percutaneous biliary drainage.

Methodology

Study population. Patients with obstructive jaundice due to locally advanced/metastatic malignancy with dilated intrahepatic bile ducts will be recruited from the department of Gastroenterology and Hepatology at the University Hospital of Leuven.

This population will have failed ERCP or will be considered when ERCP is not possible due to altered surgical anatomy.

Patients will be randomized to either PTC or EUS guided biliary drainage

Inclusion criteria:

• Patients older than 18 years presenting with malignant obstructive jaundice
• Locally advanced primary or metastatic malignancy involving the biliary tract
• Patients in whom an ERCP have failed or where an ERCP is not possible due to surgically altered anatomy (eg. Post-Whipple).

Exclusion criteria:

• Resectable biliary tract malignancy with curative intent

Endoscopic method

Linear array endoscopic ultrasound (Pentax, Pentax Hitachi, Montvale, NJ) will be used to identify the dilated left system. The Doppler mode was used to differentiate intrahepatic bile ducts from portal and hepatic vein branches. A 19G needle (Echo-19, Cook, Limerick, Ireland) will be used to puncture a peripherally located dilated segment 2 or 3 duct under EUS guidance. Under fluoroscopic control a cholangiogram will be obtained and a standard 0.035 guide-wire (Hydra Jag wire, Boston Scientific, Natick, MA Boston Scientific) will be advanced into the biliary system. Next a 6Fr cystotome (Endoflex, Voerde, Germany) will be used to create a trans-gastric tract through the liver parenchyma to the dilated biliary system. The guidewire will be manipulated across the stricture into the duodenal lumen. A Hurricane biliary dilation balloon 4cm x4mm (Boston Scientific, Natick, MA Boston Scientific) will be advanced through the tract and used to dilate the common bile duct stricture without balloon dilation at the level of the gastric wall liver interface. A 10mmx 80mm uncovered self expandable metallic stent (SEMS) will be advanced and deployed under fluoroscopy across the papilla and past the duodenal obstruction when present.

In patients were the left ductal system is not dilated, biliary access will be obtained from the duodenal bulb and a covered metal stent will be deployed in the stomach (choledocho-enterostomy).

In patients with duodenal obstruction a Wallstent will be placed at the same session as part of standard of care.

Novel research perspectives and expected outcomes

• Our research will address a very difficult clinical problem in an unique way: comparing the standard of care biliary drainage procedure (PTC) to EUS guided biliary drainage.
• We expect to demonstrate that EUS guided biliary drainage is as effective as PTC
• We also expect to show that EUS guided biliary drainage is associated with a reduced incidence of complications and reduced hospital stay.

Study endpoints

• Primary endpoints

  • Pain: Post-procedural pain as measured by visual analogue score (VAS) at 2, 24, and 72 hours following the procedures
  • Biochemical changes: Bilirubin decrease at 2 and 4 weeks

• Secondary endpoints

  • Major complications including bile leak, bleeding, sepsis or death
  • Duration of procedures in minutes
  • Length of ICU and hospital stay
  • Minor complications

Statistics power calculations It is assumed that 50% of the patients will experience prolonged pain after PTC defined as pain lasting more than 48 hours and requiring analgesics. 48 patients in total (24 per group) are then needed to detect with 80% power a difference with EUS, expecting 10% of the patients having prolonged pain after EUS. The sample size calculation is based on a two-sided Fisher's Exact test (with alpha=5%). To compensate for potential dropout, 7 additional patients in total will be recruited. Therefor the sample size will comprise of 55 patients. Exact 95% confidence intervals will be calculated for the proportion major complications in both groups. Proportions will be compared using a Fisher's Exact test. A Mann-Whitney U test will be used to compare the actual VAS scores and changes in VAS scores between groups. A log-rank test will be used to compare the length of hospital stay (LOS), censoring potential deceased patients at a value exceeding the highest observed LOS.

P-values smaller than 0.05 will be considered significant. Statistical analyses will be performed using SAS software, version 9.2 of the SAS System for Windowsld be given when defining the endpoints.

Investigators:

Department of Internal Medicine, Division of Hepatology: Prof. Frederik Nevens, Prof. Werner van Steenbergen, Prof. Chris Verslype, Prof. Wim Laleman, Prof. David Cassiman, Prof. Schalk van der Merwe

Department of Interventional radiology:

Prof. Geert Maleux, Dr. Sam Heye, Dr. Johan Vaninbroukx

• Study Type: Interventional
• Enrollment (Anticipated): 60
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Belgium
  • Leuven, Belgium, 3000
    • Recruiting
    • UZ Leuven
    • Contact: Schalk van der Merwe, MD, PhD; Phone Number: +32 16 34 42 99; Email: schalk.vandermerwe@uzleuven.be
    • Contact: Frederik Nevens, MD, PhD; Phone Number: +32 16 34 42 99; Email: frederik.nevens@uzleuven.be
    • Sub-Investigator: Frederik Nevens, MD, PhD
    • Sub-Investigator: Werner Van Steenbergen, MD, PhD
    • Sub-Investigator: Chris Verslype, MD, PhD
    • Sub-Investigator: David Cassiman, MD, PhD
    • Sub-Investigator: Wim Laleman, MD, PhD
    • Sub-Investigator: Geert Maleux, MD, PhD
    • Principal Investigator: Schalk van der Merwe, MD, PhD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients older than 18 years presenting with malignant obstructive jaundice
• Locally advanced primary or metastatic malignancy involving the biliary tract
• Patients in whom an ERCP have failed or where an ERCP is not possible due to surgically altered anatomy (eg. Post-Whipple).

Exclusion Criteria:

• Resectable biliary tract malignancy with curative intent

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Factorial Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Percutaneous Transhepatic cholangiography	Procedure: Percutaneous transhepatic cholangiography vs. endoscopic biliary drainage; Percutaneous transhepatic cholangiography biliary drainage is compared tot endoscopic biliary drainage in the management of malignant biliary obstruction not amenable to ERCP
Active Comparator: Endoscopic Ultrasound guided biliary drainage	Procedure: Percutaneous transhepatic cholangiography vs. endoscopic biliary drainage; Percutaneous transhepatic cholangiography biliary drainage is compared tot endoscopic biliary drainage in the management of malignant biliary obstruction not amenable to ERCP

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pain: Post-procedural pain as measured by visual analogue score (VAS) at 2, 24, and 72 hours following the procedures	- Primary endpoints; Pain: Post-procedural pain as measured by visual analogue score (VAS) at 2, 24, and 72 hours following the procedures; Biochemical changes: Bilirubin decrease at 2 and 4 weeks	72 hours

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Major complications including bile leak, bleeding, sepsis or death	- Secondary endpoints; Major complications including bile leak, bleeding, sepsis or death; Duration of procedures; Length of ICU stay; Minor complications	Participants will be followed for the duration of their hospital stay and for up to 4 weeks. In addition patients will be followed up to death or for a maximum period of 1 year following the procedure

Collaborators and Investigators

• Sponsor: Universitaire Ziekenhuizen KU Leuven
• Investigators: Principal Investigator: Schalk van der Merwe, MD, PhD, UZ Leuven

Study record dates

Study Major Dates

• Study Start: July 1, 2012
• Primary Completion (Anticipated): July 1, 2014
• Study Completion (Anticipated): December 1, 2014

Study Registration Dates

• First Submitted: July 10, 2012
• First Submitted That Met QC Criteria: September 17, 2012
• First Posted (Estimate): September 18, 2012

Study Record Updates

• Last Update Posted (Estimate): June 13, 2013
• Last Update Submitted That Met QC Criteria: June 12, 2013
• Last Verified: June 1, 2013

More Information

Terms related to this study

• Keywords: ERCP; Malignancy; Cholestasis; PTC; EUS-BD
• Other Study ID Numbers: ML8383